Sarepta Therapeutics (SRPT) closed at $16.42 on November 10, 2026, down 4.8% from the previous close, on volume of 3,030,659 shares (30-day average 2,417,229).
Data as of November 10, 2026.
10-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 14, 2026 | Diagonal Put Spread | 23-Oct : 13-Nov-2617.5 : 16 P | 1,042 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 10, 2026. See the 10 largest for 30, 60 and 90 days
Sarepta Updates High-Dose Eteplirsen Study in Duchenne Muscular Dystrophy
TipRanks (Tue, 10-Nov 11:30 AM ET)
TipRanks (Mon, 9-Nov 6:10 AM ET)
TipRanks (Mon, 9-Nov 5:50 AM ET)
TipRanks (Mon, 9-Nov 4:31 AM ET)
TipRanks (Sat, 7-Nov 12:40 AM ET)
Sarepta-Hansa Gene Therapy Study Ends, Raising Questions for Investors
TipRanks (Fri, 6-Nov 11:30 AM ET)
Wells Fargo Sticks to Its Buy Rating for Sarepta Therapeutics (SRPT)
TipRanks (Fri, 6-Nov 9:36 AM ET)
TipRanks (Fri, 6-Nov 9:31 AM ET)
Piper Sandler Sticks to Its Hold Rating for Sarepta Therapeutics (SRPT)
TipRanks (Fri, 6-Nov 9:16 AM ET)
Sarepta: Sell Reiterated as ELEVIDYS Erosion Weighs on Outlook; $5 Price Target Unchanged
TipRanks (Fri, 6-Nov 8:58 AM ET)
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
Sarepta Therapeutics trades on the NASDAQ stock market under the symbol SRPT.
As of November 10, 2026, SRPT stock price declined to $16.42 with 3,030,659 million shares trading.
SRPT has a beta of 2.07, meaning it tends to be more sensitive to market movements. SRPT has a correlation of 0.15 to the broad based SPY ETF.
SRPT has a market cap of $1.76 billion. This is considered a Small Cap stock.
Last quarter Sarepta Therapeutics reported $381 million in Revenue and $.13 earnings per share. This beat revenue expectation by $32 million and missed earnings estimates by -$.19.
In the last 3 years, SRPT traded as high as $173.25 and as low as $10.42.
The top ETF exchange traded funds that SRPT belongs to (by Net Assets): IJR, VTI, XBI, IWM, VB.
SRPT has underperformed the market in the last year with a price return of -4.9% while the SPY ETF gained +11.2%. SRPT has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -4.4% and -13.1%, respectively, while the SPY returned -2.7% and -2.6%, respectively.
SRPT support price is $16.62 and resistance is $17.86 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SRPT shares will trade within this expected range on the day.
